查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2067584

寡核苷酸治療藥物市場規模、佔有率和趨勢分析報告：按寡核苷酸類型、治療領域、給藥途徑、地區和細分市場預測（2026-2033 年）

Oligonucleotide Therapeutics Market Size, Share & Trends Analysis Report By Oligonucleotide Class (Antisense Oligonucleotides, Small Interfering RNA ), By Therapeutic Area, By Route of Administration, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

寡核苷酸治療藥物市場概述

全球寡核苷酸療法市場預計在 2025 年達到 72 億美元，預計到 2033 年將達到 296.838 億美元，2026 年至 2033 年的複合年成長率為 19.40%。

隨著製藥和生物技術公司越來越關注基於 RNA 的藥物，用於治療罕見遺傳疾病、腫瘤、神經系統疾病和慢性疾病，該行業正在經歷快速轉型。

反義寡核苷酸、siRNA療法和其他RNA標靶技術的加速發展，顯著拓展了基因調控藥物在多種疾病領域的治療潛力。脂質奈米顆粒和GalNAc偶聯物等遞送技術的持續創新，也推動了市場發展，提高了藥物穩定性、組織特異性靶向性、細胞內攝取率和整體治療效果。此外，法規核准的增加、臨床管線的擴展以及RNA治療方法的商業化，增強了產業信心，並刺激了全球對核酸療法研發和下一代精準醫療方法的投資。

該市場的另一個關鍵特徵是人工智慧、自動化和計算生物學等前沿技術日益融入寡核苷酸藥物的發現和開發流程。製藥和生物技術公司正積極投資於數位化藥物發現平台，以改善標靶識別、最佳化寡核苷酸設計並加速臨床前開發進程。隨著市場向更有效率、數據驅動的治療開發模式轉變，專注於RNA的生物技術公司與技術主導藥物發現公司之間的策略合作日益普遍。同時，精準醫療領域日益激烈的競爭促使各公司透過以創新為導向的合作和平台擴大策略來強化其RNA治療產品線。

目錄

第1章：調查方法和範圍

第2章執行摘要

第3章 寡核苷酸治療市場：變數、趨勢與範圍

  • 市場譜系展望
  • 市場動態
  • 商業環境分析

第4章 寡核苷酸治療市場：寡核苷酸類藥物的商業分析

  • 按寡核苷酸分類分類的市場佔有率（2025 年和 2033 年）
  • 按類型分類的寡核苷酸市場規模、預測和趨勢分析（2021-2033 年）
  • 反義寡核苷酸（ASO）
  • 小干擾RNA（siRNA）
  • 適體
  • 微型RNA（miRNA）
  • CpG寡核苷酸
  • 其他

第5章 寡核苷酸治療藥物市場：依治療領域分類的商業分析

  • 按治療區域分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：依治療領域分類，2021-2033年
  • 神經病學
  • 腫瘤學
  • 心血管代謝疾病
  • 感染疾病
  • 眼科
  • 其他

第6章 寡核苷酸治療藥物市場：依給藥途徑進行業務分析

  • 按行政途徑分類的市場佔有率，2025 年和 2033 年
  • 市場規模、預測與趨勢分析：按給藥途徑分類，2021-2033 年
  • 皮下
  • 靜脈
  • 鞘內給藥
  • 肌肉內部
  • 其他

第7章 寡核苷酸治療藥物市場：區域估算與趨勢分析

  • 2025年及2033年區域市佔率分析
  • 區域市場概覽
  • 市場規模、預測與趨勢分析，2021-2033年
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • UAE
    • 科威特

第8章 競爭情勢

  • 參與企業概況
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介列表
    • Ionis Pharmaceuticals
    • Alnylam Pharmaceuticals
    • Sarepta Therapeutics
    • Biogen
    • Novartis
    • Roche
    • Arrowhead Pharmaceuticals
    • Wave Life Sciences
    • Silence Therapeutics
    • Nitto Denko Avecia
Product Code: GVR-4-68040-924-3

Oligonucleotide Therapeutics Market Summary

The global oligonucleotide therapeutics market size was estimated at USD 7,200.00 million in 2025 and is projected to reach USD 29,608.38 million by 2033, growing at a CAGR of 19.40% from 2026 to 2033. The industry is witnessing rapid transformation as pharmaceutical and biotechnology companies increasingly focus on RNA-based medicines for the treatment of rare genetic disorders, oncology indications, neurological diseases, and chronic conditions.

Growing advancements in antisense oligonucleotides, siRNA therapeutics, and other RNA-targeting technologies are significantly expanding the therapeutic potential of gene-modulating medicines across a broad range of disease areas. The market is also benefiting from continuous innovation in delivery technologies such as lipid nanoparticles and GalNAc conjugates, which are improving drug stability, tissue-specific targeting, cellular uptake, and overall therapeutic efficiency. In addition, increasing regulatory approvals, expanding clinical pipelines, and rising commercialization of RNA-based therapies are strengthening industry confidence and encouraging broader investment in nucleic acid therapeutics development and next-generation precision medicine approaches worldwide.

Another major characteristic of the market is the increasing integration of advanced technologies such as artificial intelligence, automation, and computational biology into oligonucleotide drug discovery and development processes. Pharmaceutical companies and biotechnology firms are actively investing in digital drug discovery platforms to improve target identification, optimize oligonucleotide design, and accelerate preclinical development timelines. Strategic collaborations between RNA-focused biotechnology companies and technology-driven drug discovery firms are becoming increasingly common as the market shifts toward more efficient and data-driven therapeutic development models. At the same time, rising competition within the precision medicine landscape is encouraging companies to strengthen their RNA therapeutic pipelines through innovation-focused partnerships and platform expansion strategies.

Global Oligonucleotide Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global oligonucleotide therapeutics market report based on oligonucleotide class, therapeutic area, route of administration, and region:

  • Oligonucleotide Class Outlook (Revenue, USD Million, 2021 - 2033)
  • Antisense Oligonucleotides (ASOs)
  • Small Interfering RNA (siRNA)
  • Aptamers
  • microRNA (miRNA)
  • CpG Oligonucleotides
  • Other
  • Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
  • Neurology
  • Oncology
  • Cardiometabolic Disorders
  • Infectious Diseases
  • Ophthalmology
  • Other
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Subcutaneous
  • Intravenous
  • Intrathecal
  • Intramuscular
  • Other
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Oligonucleotide Class
    • 1.2.2. Therapeutic Area
    • 1.2.3. Route of Administration
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Oligonucleotide Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Oligonucleotide Therapeutics Market: Oligonucleotide Class Business Analysis

  • 4.1. Oligonucleotide Class Market Share, 2025 & 2033
  • 4.2. Oligonucleotide Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Oligonucleotide Class, 2021 to 2033 (USD Million)
  • 4.4. Antisense Oligonucleotides (ASOs)
    • 4.4.1. Antisense Oligonucleotides (ASOs) Market, 2021 - 2033 (USD Million)
  • 4.5. Small Interfering RNA (siRNA)
    • 4.5.1. Small Interfering RNA (siRNA) Market, 2021 - 2033 (USD Million)
  • 4.6. Aptamers
    • 4.6.1. Aptamers Market, 2021 - 2033 (USD Million)
  • 4.7. microRNA (miRNA)
    • 4.7.1. microRNA (miRNA)Market, 2021 - 2033 (USD Million)
  • 4.8. CpG Oligonucleotides
    • 4.8.1. CpG Oligonucleotides Market, 2021 - 2033 (USD Million)
  • 4.9. Other
    • 4.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Oligonucleotide Therapeutics Market: Therapeutic Area Business Analysis

  • 5.1. Therapeutic Area Market Share, 2025 & 2033
  • 5.2. Therapeutic Area Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Area, 2021 to 2033 (USD Million)
  • 5.4. Neurology
    • 5.4.1. Neurology Market, 2021 - 2033 (USD Million)
  • 5.5. Oncology
    • 5.5.1. Oncology Market, 2021 - 2033 (USD Million)
  • 5.6. Cardiometabolic Disorders
    • 5.6.1. Cardiometabolic Disorders Market, 2021 - 2033 (USD Million)
  • 5.7. Infectious Diseases
    • 5.7.1. Infectious Diseases Market, 2021 - 2033 (USD Million)
  • 5.8. Ophthalmology
    • 5.8.1. Ophthalmology Market, 2021 - 2033 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Oligonucleotide Therapeutics Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2025 & 2033
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
  • 6.4. Subcutaneous
    • 6.4.1. Subcutaneous Market, 2021 - 2033 (USD Million)
  • 6.5. Intravenous
    • 6.5.1. Intravenous Market, 2021 - 2033 (USD Million)
  • 6.6. Intrathecal
    • 6.6.1. Intrathecal Market, 2021 - 2033 (USD Million)
  • 6.7. Intramuscular
    • 6.7.1. Intramuscular Market, 2021 - 2033 (USD Million)
  • 6.8. Others
    • 6.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Oligonucleotide Therapeutics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Oligonucleotide Therapeutics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. Canada Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Brazil Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. Argentina Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Oligonucleotide Therapeutics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Ionis Pharmaceuticals
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Alnylam Pharmaceuticals
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Sarepta Therapeutics
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Biogen
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Novartis
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Roche
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Arrowhead Pharmaceuticals
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Wave Life Sciences
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Silence Therapeutics
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Nitto Denko Avecia
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global oligonucleotide therapeutics market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 5 Global oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 6 Global oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 7 North America oligonucleotide therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 9 North America oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 10 North America oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 11 U.S. oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 12 U.S. oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 13 U.S. oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 14 Canada oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 15 Canada oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 16 Canada oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 17 Mexico oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 18 Mexico oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 19 Mexico oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 20 Europe oligonucleotide therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 22 Europe oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 23 Europe oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 24 UK oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 25 UK oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 26 UK oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 27 Germany oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 28 Germany oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 29 Germany oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 30 France oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 31 France oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 32 France oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 33 Italy oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 34 Italy oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 35 Italy oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 36 Spain oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 37 Spain oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 38 Spain oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 39 Norway oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 40 Norway oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 41 Norway oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 42 Denmark oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 43 Denmark oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 44 Denmark oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 45 Sweden oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 46 Sweden oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 47 Sweden oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific oligonucleotide therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 52 Japan oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 53 Japan oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 54 Japan oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 55 China oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 56 China oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 57 China oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 58 India oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 59 India oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 60 India oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 61 Australia oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 62 Australia oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 63 Australia oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 64 South Korea oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 65 South Korea oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 66 South Korea oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 67 Thailand oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 68 Thailand oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 69 Thailand oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 70 Latin America oligonucleotide therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 71 Latin America oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 72 Latin America oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 73 Latin America oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 74 Brazil oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 75 Brazil oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 76 Brazil oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 77 Argentina oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 78 Argentina oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 79 Argentina oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa oligonucleotide therapeutics market, by country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 84 South Africa oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 85 South Africa oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 86 South Africa oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 90 UAE oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 91 UAE oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 92 UAE oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)
  • Table 93 Kuwait oligonucleotide therapeutics market, by oligonucleotide class, 2021 - 2033 (USD Million)
  • Table 94 Kuwait oligonucleotide therapeutics market, by therapeutic area, 2021 - 2033 (USD Million)
  • Table 95 Kuwait oligonucleotide therapeutics market, by route of administration, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Oligonucleotide therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Oligonucleotide therapeutics market dynamics
  • Fig. 11 Oligonucleotide therapeutics market: Porter's five forces analysis
  • Fig. 12 Oligonucleotide therapeutics market: PESTLE analysis
  • Fig. 13 Oligonucleotide class market, 2021 - 2033 (USD Million)
  • Fig. 14 Antisense oligonucleotides (ASOs) market, 2021 - 2033 (USD Million)
  • Fig. 15 Small interfering RNA (siRNA) market, 2021 - 2033 (USD Million)
  • Fig. 16 Aptamers market, 2021 - 2033 (USD Million)
  • Fig. 17 microRNA (miRNA) market, 2021 - 2033 (USD Million)
  • Fig. 18 CpG oligonucleotides market, 2021 - 2033 (USD Million)
  • Fig. 19 Other market, 2021 - 2033 (USD Million)
  • Fig. 20 Therapeutic area market, 2021 - 2033 (USD Million)
  • Fig. 21 Neurology market, 2021 - 2033 (USD Million)
  • Fig. 22 Oncology market, 2021 - 2033 (USD Million)
  • Fig. 23 Cardiometabolic disorders market, 2021 - 2033 (USD Million)
  • Fig. 24 Infectious diseases market, 2021 - 2033 (USD Million)
  • Fig. 25 Ophthalmology market, 2021 - 2033 (USD Million)
  • Fig. 26 Other market, 2021 - 2033 (USD Million)
  • Fig. 27 Route of administration market, 2021 - 2033 (USD Million)
  • Fig. 28 Subcutaneous market, 2021 - 2033 (USD Million)
  • Fig. 29 Intravenous market, 2021 - 2033 (USD Million)
  • Fig. 30 Intrathecal market, 2021 - 2033 (USD Million)
  • Fig. 31 Intramuscular market, 2021 - 2033 (USD Million)
  • Fig. 32 Other market, 2021 - 2033 (USD Million)
  • Fig. 33 Oligonucleotide therapeutics market revenue, by region
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 North America Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 36 U.S. country dynamics
  • Fig. 37 U.S. Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 38 Canada country dynamics
  • Fig. 39 Canada Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 40 Mexico country dynamics
  • Fig. 41 Mexico Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 42 Europe Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 43 UK country dynamics
  • Fig. 44 UK Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 45 Germany country dynamics
  • Fig. 46 Germany Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 47 France country dynamics
  • Fig. 48 France Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 49 Italy country dynamics
  • Fig. 50 Italy Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 51 Spain country dynamics
  • Fig. 52 Spain Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 53 Norway country dynamics
  • Fig. 54 Norway Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 55 Sweden country dynamics
  • Fig. 56 Sweden Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 57 Denmark country dynamics
  • Fig. 58 Denmark Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 59 Asia Pacific Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 60 Japan country dynamics
  • Fig. 61 Japan Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 62 China country dynamics
  • Fig. 63 China Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 64 India country dynamics
  • Fig. 65 India Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 66 Australia country dynamics
  • Fig. 67 Australia Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 68 South Korea country dynamics
  • Fig. 69 South Korea Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 70 Thailand country dynamics
  • Fig. 71 Thailand Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 72 Latin America Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 73 Brazil country dynamics
  • Fig. 74 Brazil Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 75 Argentina country dynamics
  • Fig. 76 Argentina Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 77 MEA Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 78 South Africa country dynamics
  • Fig. 79 South Africa Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 80 Saudi Arabia country dynamics
  • Fig. 81 Saudi Arabia Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 82 UAE country dynamics
  • Fig. 83 UAE Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 84 Kuwait country dynamics
  • Fig. 85 Kuwait Oligonucleotide therapeutics market, 2021 - 2033 (USD Million)
  • Fig. 86 Company categorization
  • Fig. 87 Company market position analysis
  • Fig. 88 Strategic framework